Vaccines remain the most effective way of preventing infection and spread of infectious diseases. These prophylactics have been used for centuries but still to this day only three main design strategies exist: (1) live attenuated virus (LAV) vaccines, (2) killed or inactivated virus vaccines, (3) and subunit vaccines of the three, the most effi cacious vaccines remain LAVs. LAVs replicate in relevant tissues, elicit strong cellular and humoral responses, and often confer lifelong immunity. While this vaccine strategy has produced the majority of successful vaccines in use today, there are also important safety concerns to consider with this approach. In the past, the development of LAVs has been empirical. Blind passage of viruses in various cell types results in the accumulation of multiple attenuating mutations leaving the molecular mechanisms of attenuation unknown. Also, due to the high error rate of RNA viruses and selective pressures of the host environment, these LAVs, derived from such viruses, can potentially revert back to wild-type virulence. This not only puts the vaccinee at risk, but if shed can put those that are unvaccinated at risk as well. While these vaccines have been successful there still remains a need for a rational design strategy by which to create additional LAVs.
Introduction
LAVs remain the most effective strategy for vaccine design [ 1 , 2 ] . However, in the past developments of these vaccines have been empirical. Blind passage of viruses in different cell types results in the accumulation of multiple attenuating mutations leaving the molecular mechanisms of attenuation unknown. Due to the high error rate of RNA viruses and the selective pressures of the host environment, these LAVs can potentially revert back to wild-type virulence. This not only puts the vaccinee at risk, but if shed can put those that are unvaccinated at risk as well. LAV vaccines have been created against a number of RNA viruses, such as poliomyelitis, measles, mumps, rabies, rubella, yellow fever and infl uenza. While these vaccines have been successful there still remains a need for a rational design strategy in which to create additional LAVs. It has been shown that by altering fi delity, the rate and speed at which the polymerase incorporates mutations, leads to viral attenuation [ 3 -8 ] .
RNA viruses are defi ned by high mutation rates, high yields, and short replication times. These viruses have an average mutation rate of 10 −3 to 10 −5 mutations per genome replication event [ 4 ] . As a result, RNA viruses do not replicate as a single sequence but as a "cloud" of mutant genomes, which have been dubbed quasispecies [ 9 -12 ] . Although a high mutation rate can lead to deleterious changes in the genome, genetic diversity in RNA virus populations appears to be critical for fi tness and survival and likely contributes to pathogenesis. In a heterogeneous pathogen population, some variants are able to infect primary tissues and bypass host-imposed bottlenecks. From here the remaining variants can replicate into another heterogeneous population where some are once again able to bypass another layer of bottlenecks and perform secondary infection in other tissues thus demonstrating that a heterogeneous population, or quasispecies, can be benefi cial to the pathogen. This adaptability poses a unique challenge, for example, when it comes to developing antiviral drugs and vaccines.
RNA virus populations are heterogeneous due to error-prone replication by the viral RNA-dependent RNA polymerase (RdRp) which infl uences quasispecies evolution. This adaptability benefi ts the pathogen sometimes at the cost of the host. Currently, error-prone replication is known to happen in all RNA viruses that infect both plants and animals. It is also known that this error is due to rapid generation of variants and the fi delity of the viral RdRp [ 13 -15 ] .
In order to study the effect of polymerase mutants on RNA virus heterogeneity, we turn to a model RNA virus, poliovirus. Poliovirus (PV) belongs to the family Picornaviridae . This family consists of non-enveloped, positive single strand genomes many of which are important human and animal pathogens. The PV genome can be divided into three parts, the 5′-untranslated region (5′-UTR), a single open reading frame (ORF), and the polyadenylated 3′-untranslated region (3′ UTR). Upon entry into the cell, the mRNA is translated as a polyprotein of approximately 3000 amino acids and can be divided into three functionally different regions: P1, P2, and P3. The polyprotein is cleaved cotranslationally and posttranslationally by viral proteases 2A pro and 3C pro into 11 proteins. The PV RdRP is found in the P3 region and is termed 3Dpol.
The RdRp is one out of four categories of polymerases and its crystal structure shows a close evolutionary relationship not only to other RdRps but also to that of DNA-dependent DNA-polymerases (DdDps), DNA-dependent RNA-polymerases (DdRps), and RNAdependent DNA-polymerases (RdDps) also known as reverse transcriptases (RTs). All resemble a cupped right-handed structure consisting of the thumb, fi ngers, and palm subdomains [ 16 , 17 ] . The palm is where the active site of the polymerase lies and consists of four conserved structural motifs A-D [ 16 ] . A fi fth and sixth motif, E and F, exists in the RNA-dependent polymerases but not the DNA-dependent polymerases [ 16 ] . The latter motifs are not in the active site but line this region. RdRps are error prone but they are as faithful as DNA polymerases that lack proofreading exonucleases [ 18 ] . The absence of a repair mechanism in the PV genome is what leads to an enhanced rate of mutation during viral replication.
Nucleic acid polymerases use a two-metal-ion mechanism for nucleotidyl transfer [ 19 ] . In this mechanism, two magnesium ions are used to organize the reactants. Recently, the chemical mechanism of nucleotidyl transfer has been expanded to include a general acid, which protonates the pyrophosphate leaving group of the NTP substrate and enhance the effi ciency of nucleotidyl transfer [ 20 , 21 ] . The general acid of PV RdRp is Lys359, located in motif D, which is conserved throughout all RdRps and RTs. Importantly, an orthologous residue at this site is known or predicted in RNA viruses for which rational design of vaccines would greatly benefi t.
In order to determine what effect biochemical changes have on the multiplication of the virus in cell culture we created a PV genome encoding the arginine mutation in the PV subgenomic replicon (pRLucRA) and viral cDNA (pMoVRA). Quantifi cation of virus by plaque assay provides insight into fi tness of the viral population. The subgenomic replicon permits indirect evaluation of RNA synthesis by measurement of luciferase activity. Analysis of RNA replication in the absence of virus production can provide insight on whether RNA replication is the rate-limiting step for virus production.
The characteristics of live-virus multiplication and their plaque phenotype can predict whether the virus will be attenuated in the mouse model. However, viral quantifi cation by plaque forming units (pfu) selects variants based on phenotype and therefore can be an unreliable measure of viruses present due to phenotypic differences between viral strains. In addition to pfu, quantifying virus based on genomes accounts for total viral particles produced. This is a more accurate measurement of total viruses in the population and the number of genomes produced by the polymerase.
While these characteristics predict attenuation, actual confi rmation is determined using a mouse transgenic for the PV receptor. In this system, wild-type (WT) PV is generally lethal. At the highest dose, the mutated polymerase (lysine to arginine) failed to
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cause disease in the mice. To determine if the mutant virus replicated, mice surviving the initial infection were challenged with a lethal dose of WT PV. We can conclude from the mice that survive this challenge, the mutant is replication competent and elicits an immune response suffi cient enough to protect against a lethal dose of WT PV [ 3 ] .
Using PV as our model we have developed a rational design for polymerase-based mechanism of attenuation. By altering the nature of the general acid lysine residue to an arginine, we have shown that we maintain the ability to tune RdRp speed and fi delity creating a viral RdRp that is slower and more faithful than the WT enzyme. This results in an attenuated virus with a restricted viral quasispecies that fails to cause disease, yet elicits a protective immune response. This approach has the ability to be applied to any RNA virus given the conserved nature of the motif D lysine residue. Table 1 is an alignment of residues found in motif D of the RdRp for positive and negative strand RNA virus families. Numbers indicate the position from the fi rst amino acid of motif D in the RdRp domain. The conserved lysine residue is shown in boldfaced type. Other conserved residues are underlined. All sequences were obtained from the NCBI Database. Sequences were aligned using ClustalW2 and based upon alignments previously published [ 22 ] .
Materials
1. Poliovirus Mahoney cDNA, pMoVRA, and subgenomic replicon pRLucRA [ 23 ] .
2. External primers, diluted to 5 μM concentrations.
(a) Forward: PV-3D-BglII-for (5′-TAG AGG ATC CAG ATC TTG GAT GCC A-3′). 
Methods
The polymerase gene was amplifi ed using pMoV-3D-BPKN plasmid as a template. This template has silent mutations engineered into the 3Dpol coding sequence. The "naked" viral cDNA, pMoVRA, contains 4 Pst I restriction sites and pRLucRA contains 3. A Pst I site was engineered into the 3Dpol coding sequence such that when cloned into the "naked" vectors, pMoVRA and pRLu-cRA, and digested with Pst I, positive clones containing the mutated PCR product will have 5 and 4 bands respectively when run on a agarose gel. Clones positive by restriction digest are verifi ed for the presence of the mutation by sequencing.
PCR reaction A:
(a) External forward primer: PV-3D-BglII-for.
(b) Internal reverse primer: PV-3D-K359R-rev.
2. Perform amplifi cation reactions in three separate 100 μL volumes, fi nal concentration containing: 1× Thermopol buffer, 3 mM dNTPs, 0.5 μM of each primer, 0.5 ng/μL of template plasmid pMo-3D-BPKN, and 2 U of Deep Vent Polymerase ( Table 2 ).
3. Cycling conditions consist of a preliminary denaturing step at 95 °C for 4 min followed by a hot start cycle for 4 cycles at 95, 50, and 72 °C each for 1 min and fi nally, 18-20 cycles of denaturation at 95 °C for 1 min, annealing at 57 °C for 1 min and product extension at 72 °C for 2 min and a fi nal product extension at 72 °C for 10 min.
4. Prepare 2, 1.2 % agarose gels.
5. The rest of product tubes are combined and DNA is precipitated with 100 % ethanol. Add 1/5th volume (60 μL) 3 M NaOAc, mix well with pipet then add three volumes (1080 μL) 100 % EtOH and mix well. Freeze mixture on dry ice until liquid is a slow moving "sludge" when inverted. Centrifuge at top speed for 10 min. You will observe a thick white pellet. (a) External reverse primer: PV-3D-EcoRI-ApaI-polyA-rev.
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(b) Internal forward primer: PV-3D-K359R-for. 9 . Same procedure as for PCR reaction A (Table 3 ) . 10 . Repeat concentration and purifi cation a for PCR A.
1. Set up 3-100 μL reactions as before this time using PCR reactions A and B as templates (Table 4 ):
(b) External reverse primer: PV-3D-EcoRI-ApaI-polyA-rev.
2. Concentrate and purify PCR product as previously described for PCR products A and B. 
Round Two: Overlap PCR
First, digest cDNA and overlap PCR fragment with
Bgl II. Digest purifi ed cDNA by adding 2 μg of DNA to a 1.5 mL tube containing 10 μL of the appropriate 10× restriction buffer with 4 μL (40 U) of enzyme in a total volume of 100 μL and incubate according to manufacturer's instructions. We recommend 2-4 h for an incubation time. For the purifi ed overlap PCR product, repeat the same procedure as above, using the entire 50 μL product in the digest ( Table 5 ).
3. Allow reaction to proceed at 37 °C for 2 h.
4. Run a sample of uncut and cut plasmids on 1 % agarose gel to check effi ciency of reaction ( see Note 3 ).
5.
When you have verifi ed that the plasmid has been linearized, purify with QIAEX II gel extraction kit. Follow the kit's protocol for purifying and concentrating DNA from an aqueous solution.
6. Clean up DNA using QIAEX II gel extraction kit. Follow the kit's protocol for purifying and concentrating DNA from an aqueous solution.
7. Suspend silica bead pellet in 50 μL T 10 E 0.1 and incubate at 65 °C for 10 min.
8. Quick spin the tube and remove both supernatant and beads and add to Spin-X fi lter tube. Spin at 800 × g for 5 min and collect eluted DNA from tube. 9. Digest purifi ed cut cDNA by adding entire 50 μL of cut DNA to a 1.5 mL tube containing 10 μL of the appropriate 10× restriction buffer with 1 μL (50 U) of enzyme in a total volume of 100 μL and incubate according to manufacturer's instructions. We recommend 2-4 h for incubation time. For the purifi ed cut overlap PCR product, repeat the same procedure as above (Table 6 ).
Cloning PCR Fragment into pMoVRA and pRLucRA Vectors
Vector and PCR Fragment Digest
10. Allow reaction to proceed at 25 °C (about room temperature) for 2 h.
11. After the 2 h incubation with Apa I to the cDNA only digest, add 4 μL (4 U) of shrimp alkaline phosphatase to reaction. Incubate at 37 °C for 4 h to overnight in order to 1. pMoV-3D-K359R and pRLuc-3D-K359R plasmids are fi rst linearized with restriction enzyme Apa I.
2. Digest purifi ed cDNA by adding 5 μg of mutant plasmid to a 1.5 mL tube containing 10 μL of the appropriate 10× restriction buffer with 2.5 μL (50 U) of enzyme in a total volume of 100 μL and incubate according to manufacturer's instructions. We recommend 2-4 h for incubation time (Table 8 ).
3. Run a sample of uncut and cut plasmids on 1 % agarose gel to check effi ciency of reaction ( see Note 3 ).
4.
5. Suspend silica bead pellet in 50 μL T 10 E 0.1 and incubate at 65 °C for 10 min.
6. Quick spin the tube and remove both supernatant and beads and add to Spin-X tube. Spin at 800 × g for 5 min and collect eluted DNA from tube.
7. Add H 2 O fi rst; subtract the DNA volume from 2.5 μL to get the volume of H 2 O to be added.
8. Next add the following in this order to a total volume of 20 μL, fi nal concentration containing: 350 mM HEPES, 32 mM MgAcetate, 40 mM DTT, 2 mM spermidine, 28 mM NTPs, 0.5 μg linearized cDNA, and 0.5 μg T7 RNAP into an autoclaved 0.6 mL microcentrifuge tube (Table 9 ).
9. Pre-incubate the reaction mix at 37 °C for 5 min prior to adding T7 RNAP.
10. Add T7 RNAP.
11. Incubate reaction at 37 °C. After 30 min, check reaction for cloudy, white precipitate, which is magnesium pyrophosphate forming, to ensure the reaction is progressing. Allow reaction 5. Add 400 μL of HeLa cell suspension to 1.7 mL tube of RNA. Quickly add the mixture to the cuvette and place cuvette into chamber and zap cells. Using media from 15 mL conical (pre-warmed from water bath) add 600 μL of media to zapped cells still in the cuvette. Gently pipet up and down multiple times to mix cells and media and to break up any cell clumps that may have formed. Table 8 Linearization of cDNA
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cDNA Linearization and In Vitro T7 Transcription Reaction
RNA Transfection
Reagent Volume (μL)
10× NEB cut smart buffer 10
Apa I (50 U/μL) 2.5 5 μg cDNA -
Reaction volume
1. Prepare 15 mL conical tubes with 5.6 mL of complete media. Set them aside in 37 °C water bath until needed.
2. Proceed with RNA transfection as described previously ( see RNA transfection).
3. Add 600 μL of media to zapped cells still in the cuvette. Gently pipet up and down multiple times to mix cells and media and to break up any cell clumps that may have formed.
4. Add cell and media mixture back to 15 mL conical tube. Close the tube and gently invert back and forth to mix. Aliquot 500 μL into a 1.7 mL tube and place the 15 mL conical in the 37 °C incubator until ready to take next timepoint.
5. Spin the one 1.7 mL tube at 2500 × g for 2 min for 0 h time point.
6. Remove media and wash pellet with 1× PBS. Spin again. Remove 1× PBS and add 100 μL of 1× CCLR (diluted to 1× in ddH 2 O). Vortex tube for 10 s and place on ice.
7. Repeat this for every time point taken and leave all cells on ice until the next day. Make that each time an 500 μL aliquot is removed from the 15 mL conical tube that the tube is inverted multiple times to ensure an even distribution of cells. 8. Next day, vortex cells again for 10 s and spin down at max speed for 5 min to pellet any cellular debris.
Luciferase Assay
9. Transfer 10 μL of supernatant to 12 × 75 mm glass borosilicate assay tube. Let sit for 10-15 min then add 10 μL of luciferase substrate. Immediately place into luminometer and read light output.
The infectious center assay is used to determine the fraction of cells within a culture that are infected with virus after RNA transfection. In this case, the infected cells are suspended, counted, and plated onto monolayers of susceptible cells, which are then overlaid with agar. The number of plaques provides a measure of the number of virus infected cells in the original culture, thus how infectious the in vitro transcribed RNA is.
1. One day before seed 6-well plates with 6 × 10 5 HeLa S3 cells per well and cover with 3 mL complete media.
2. Next day, follow procedure for in vitro RNA transfection. 6 ).
20. To analyze one-step virus growth, infected cells with virus at a multiplicity of infection (MOI) 10. Allow virus to adsorb to cells for 30 min and wash with 1× PBS then add 1 mL of complete media to cells.
21. Incubated at 37 °C and harvest cells and media using a sterile disposable spatula (to scrape cells off the bottom of the well) at various time points post-infection. Virus and cell mixture is put into autoclaved 1.7 mL microcentrifuge tubes and immediately frozen on dry ice.
22.
Harvest virus by three repeated freeze-thaw cycles and quantitate virus titers as described above.
23. Also extract RNA using Qiagen RNeasy Plus Mini Kit to determine genomes/mL by RT-qPCR.
7. Observe mice for 14 days for signs of disease (ruffl ed fur and general malaise) and euthanize upon mice showing dual limb paralysis or paralysis such that their ability to obtain food and water is compromised.
8. After 14 days, determine PD 50 values by the Reed and Muench method.
1. Mice previously infected with mutants, or surviving mice (from PD 50 experiment) were challenged 1 month after initial infection using the same methods with 5× PD 50 of WT poliovirus by i.p. injection and observed for 14 days as before.
Notes
1. The AAA codon encoding the lysine was changed to CGT codon encoding arginine. This genetic reversion requires two transversion mutations, which is a very ineffi cient event thus providing some barrier to reversion.
2. When using new primers, test the effi ciency of the reaction by titrating in MgSO 4 . Set up 3-100 μL reactions and add 0, 1, and 2 μL of the 100 mM MgSO 4 . Run 10 μL of completed product on agarose gel to check effi ciency of reaction. Combine the successful reaction tubes and precipitate out DNA for gel purifi cation.
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Lethal Dose Fifty (LD 50 )/Paralysis Dose Fifty (PD 50 ) Analysis Components
Protection
3. Combine water, cDNA and buffer in 1.7 mL tube and before adding enzyme to your reaction, remove 5 μL from the tube and set aside. This will be your "uncut" sample. Add the enzyme and allow reaction to proceed at proper temperature. After incubation remove another 5 μL from the tube. This will be your "cut" sample.
4. The number of colonies after successful ligation and transformation of cloned pMoVRA and pRLucRA yield different results. When plating 100 % of your transformed cells, the pMoVRA clone should yield roughly 50 colonies on a plate, whereas the pRLucRA clone will yield at most 100 colonies.
5.
Multiple freeze thaws of virus stock will overtime lower the titer of the virus. To avoid this, make small aliquots of virus and store at −80 °C. Never use a stock tube that has been thawed more than three times after a titer or genome copy has been determined.
6. There are two reasons why it is important to passage virus at a low MOI. First is to check the stability of the engineered mutation by sequencing the mutated region; second is to generate a quasispecies.
